Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Andrew, Geall"'
Autor:
Alvaro Baeza Garcia, Edwin Siu, Tiffany Sun, Valerie Exler, Luis Brito, Armin Hekele, Gib Otten, Kevin Augustijn, Chris J. Janse, Jeffrey B. Ulmer, Jürgen Bernhagen, Erol Fikrig, Andrew Geall, Richard Bucala
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Plasmodium species produce an ortholog of the cytokine macrophage migration inhibitory factor, PMIF, which modulates the host inflammatory response to malaria. Here, the authors show that inhibition of PMIF may have translational benefits for managin
Externí odkaz:
https://doaj.org/article/be49eab245d7481c9136ee80bc91bed8
Autor:
Barbora Malecova, Rob S Burke, Michael Cochran, Michael D Hood, Rachel Johns, Philip R Kovach, Venkata R Doppalapudi, Gulin Erdogan, J Danny Arias, Beatrice Darimont, Christopher D Miller, Hanhua Huang, Andrew Geall, Husam S Younis, Arthur A Levin
Publikováno v:
Nucleic Acids Research.
Although targeting TfR1 to deliver oligonucleotides to skeletal muscle has been demonstrated in rodents, effectiveness and pharmacokinetic/pharmacodynamic (PKPD) properties remained unknown in higher species. We developed antibody–oligonucleotide c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e257c1cb5d93c7540c6e8125093ab60d
https://doi.org/10.1093/nar/gkad415
https://doi.org/10.1093/nar/gkad415
Autor:
Molly M. Stevens, Paul Rogers, Kai Hu, Robin J. Shattock, Krunal Polra, Andrew Geall, Jonathan Yeow, Anna K. Blakney, Yunqing Zhu, Paul F. McKay, Andrew F. Brown, Karnyart Samnuan, Nikita Jain, Hadijatou Sallah, Anitha Thomas
Publikováno v:
Journal of Controlled Release
Self-amplifying RNA (saRNA) is a next-generation vaccine platform, but like all nucleic acids, requires a delivery vehicle to promote cellular uptake and protect the saRNA from degradation. To date, delivery platforms for saRNA have included lipid na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdf18f2f7ebfc89c9c8c7180a6c228df
http://europepmc.org/articles/PMC8412240
http://europepmc.org/articles/PMC8412240
Autor:
Kaustuv Banerjee, Julie Hickman, Andrew Geall, Jeffrey B. Ulmer, Gleb Kichaev, Niranjan Y. Sardesai, Yen Cu, Susan Barnett, Gillis Otten, Kate E. Broderick
Publikováno v:
Vaccines, Vol 1, Iss 3, Pp 367-383 (2013)
Nucleic acid-based vaccines such as viral vectors, plasmid DNA (pDNA), and mRNA are being developed as a means to address limitations of both live-attenuated and subunit vaccines. DNA vaccines have been shown to be potent in a wide variety of animal
Externí odkaz:
https://doaj.org/article/799c4c592bf54ec88a808996ec1146ab
Autor:
Sebastian Kreiter, Mustafa Diken, Steve Pascolo, Smita K. Nair, Kris M. Thielemans, Andrew Geall
Publikováno v:
Journal of Immunology Research, Vol 2016 (2016)
Externí odkaz:
https://doaj.org/article/15e26a04a88849bb9c91eb39d40d5731
Autor:
Peter W. Mason, Clayton W. Beard, Lesley C. Dupuy, Jeffrey B. Ulmer, Dong Yu, Carolyn M. Six, Andrew Geall, Connie S. Schmaljohn, Marcelo M. Samsa
Publikováno v:
Molecular Therapy. 27:850-865
Venezuelan equine encephalitis virus (VEEV) is a known biological defense threat. A live-attenuated investigational vaccine, TC-83, is available, but it has a high non-response rate and can also cause severe reactogenicity. We generated two novel VEE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87c60119f751632d1516de037d1e52ee
https://doi.org/10.1016/j.ymthe.2018.12.013
https://doi.org/10.1016/j.ymthe.2018.12.013
Publikováno v:
Vaccines
Vaccines, Vol 9, Iss 97, p 97 (2021)
Vaccines, Vol 9, Iss 97, p 97 (2021)
This review will explore the four major pillars required for design and development of an saRNA vaccine: antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)). In will report on the ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::309b0dbcea91943efd9caacd49365a79
https://pubmed.ncbi.nlm.nih.gov/33525396
https://pubmed.ncbi.nlm.nih.gov/33525396
Autor:
Farid Sari-Sarraf, Gillis R. Otten, Timothy Pepini, Thomas Carsillo, Carlo Iavarone, Jeffrey B. Ulmer, Dong Yu, Alicia L. Carlson, Giulietta Maruggi, Jason C. Debasitis, Katrin Ramsauer, Anne-Marie Pulichino, Andrew Geall
Publikováno v:
The Journal of Immunology. 198:4012-4024
RNA-based vaccines have recently emerged as a promising alternative to the use of DNA-based and viral vector vaccines, in part because of the potential to simplify how vaccines are made and facilitate a rapid response to newly emerging infections. SA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13bb56454b7ca4b588da1373c4fa5482
https://doi.org/10.4049/jimmunol.1601877
https://doi.org/10.4049/jimmunol.1601877
Autor:
Immaculada Margarit, Giuliano Bensi, Domenico Maione, Emiliano Chiarot, Stefano Bonacci, Andrew Geall, Scilla Buccato, Giulietta Maruggi, Elisabetta Frigimelica, Cinzia Giovani
Publikováno v:
Vaccine. 35:361-368
Nucleic acid vaccines represent an attractive approach to vaccination, combining the positive attributes of both viral vectors and live-attenuated vaccines, without the inherent limitations of each technology. We have developed a novel technology, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1c5b869c0c7d63a354736b453c47915
https://doi.org/10.1016/j.vaccine.2016.11.040
https://doi.org/10.1016/j.vaccine.2016.11.040
Autor:
Jeffrey B. Ulmer, Andrew Geall
Publikováno v:
Current Opinion in Immunology. 41:18-22
Nucleic acid-based vaccines are being developed as a means to combine the positive attributes of both live-attenuated and subunit vaccines. Viral vectors and plasmid DNA vaccines have been extensively evaluated in human clinical trials and have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10a2ab7c36f543d89769df083cd95389
https://doi.org/10.1016/j.coi.2016.05.008
https://doi.org/10.1016/j.coi.2016.05.008